Loved attending the Brazil Global Health Initiative event yesterday at Stanford. Always inspiring to connect with brilliant Brazilian researchers doing amazing work across Silicon Valley. Proud to be part of this community! 🇧🇷
I had the privilege of sharing the stage with Drs. J. John Mann (Columbia), my incredible mentor, Alan Schatzberg (Stanford), Mina Rizk (Mount Sinai), and Yunyu Xiao (Cornell) for a thoughtful exchange on innovative approaches to suicide prevention.
What an experience at #ACNP2026! Honored to present our Stanford randomized clinical trial demonstrating a novel strategy to sustain the antisuicidal effects of #ketamine in #depression as part of our mini-panel on buprenorphine and suicidality. @acnporg.bsky.social
Grateful to be back at #ACNP2026, supported by my Past Travel Awardee Funding!
I'm a Stanford postdoc leading trials in interventional psychiatry with #BrainStimulation and #Ketamine for depression and suicide prevention. Join our mini-panel on 01/13 and poster on 01/15! @acnporg.bsky.social
Check out our new commentary in the International Journal of Neuropsychopharmacology (@ijnp.bsky.social) on ketamine–naltrexone clinical trial design for depression.
doi.org/10.1093/ijnp...
Thank you very much!
Privileged our mini-panel was selected for #ACNP2026 @acnporg.bsky.social. Grateful to join Drs. J. John Mann (Columbia), Alan Schatzberg (Stanford), Mina Rizk (Mount Sinai) and Yunyu Xiao (Cornell). Looking forward to the discussions ahead!
Proud to receive the American College of Neuropsychopharmacology (ACNP) Past Travel Awardee Funding, recognizing my ongoing research progress. #ACNP2025 @acnporg.bsky.social
Dr Luke Jelen, lead author of the study and a Clinical Lecturer in Psychiatry at IoPPN King’s College London, said: “Ketamine often makes the news for negative reasons. However, at a low dose, ketamine shows enormous potential to offer relief from the symptoms of depression.” “Understanding whether the opioid system is involved ketamine’s antidepressant effects is a really important question, given how much we still don't know about how ketamine works. “Our study shows that the opioid system is involved and offers insight into how it contributes to ketamine’s effects.”
Research which is investigating why ketamine could be a good treatment for some people with depression, has discovered that the drug’s antidepressant effects involve the brain’s opioid system.
The study was supported by @nihr.bsky.social and the MRC.
www.maudsleybrc.nihr.ac.uk/posts/2025/j...
Spoke with @peerj.bsky.social about my research after receiving 1st Prize for Best Poster at the Winter Conference on Brain Research 2025. #WCBR2025
peerj.com/blog/post/11...
Grateful for the chance to share what drives my work in interventional psychiatry.
In this chapter, we explore the evolving landscape of substances with abuse potential (including #ketamine and #psychedelics) being repurposed for therapeutic use in #bipolardisorder, highlighting both their promise and the risks involved.
Read more: link.springer.com/chapter/10.1...
Thrilled to share that our book chapter has just been published as part of #Bipolar Disorder: An Evidence-Based Clinical Guide (Springer Nature, 2025).
This recognition not only supports early-career researchers like myself, but also strengthens our collective mission to advance evidence-based care for depression and suicidality. #ADAA2025
I’m deeply grateful to the Anxiety and Depression Association of America (@adaaanxiety.bsky.social) for honoring me with the Alies Muskin Career Development Leadership Award this year. #ADAA2025
The fourth annual Suicide Research Symposium (#SRS25) takes place THIS WEEK, Wednesday (April 23) through Friday (April 25)! Registration is still open for our free, virtual event. Links to register and see the conference platform are on our website: www.suicideresearchsymposium.com
I will present preliminary data from our randomized clinical trial (clinicaltrials.gov/study/NCT041...), examining the impact of chronic pain on #ketamine response in treatment-resistant #depression. I look forward to sharing our findings! #suicideprevention
Happy to share that I have been selected for the Alies Muskin Career Development Leadership Award from the Anxiety and Depression Association of America (@adaaanxiety.bsky.social)! #ADAA2025
A heartfelt thank you to my collaborators, mentors, research team, and the patients who made this work possible!
Our trial is investigating the efficacy and safety of buprenorphine in prolonging the antisuicidal and antidepressant effects of ketamine (clinicaltrials.gov/study/NCT041...), and the final results are coming soon!
It was a great honor to receive the New Investigator Award and share the preliminary data from our @afspnational.bsky.social study at the 21st Annual Meeting of the International Society for CNS Clinical Trials and Methodology in Washington, DC. #ISCTM2025
A huge thank you to my mentors, colleagues, and collaborators who have supported my journey. I look forward to engaging with the ISCTM community and contributing to discussions on clinical trial methodology in psychiatry!
Honored to have been selected for the New Investigator Award from the International Society for CNS Clinical Trials and Methodology! This recognition aligns with my passion for advancing rigorous and innovative research methodologies to improve psychiatric care. #ISCTM #ISCTM2025
First prize for Best Poster Presentation at the Winter Conference on Brain Research 2025! This recognition is a reminder that perseverance pays off, even in challenging times. Proud and grateful! #WCBR #WCBR2025
The film challenges us to embrace the chaos of difficult times, using them not as reasons to retreat but as fuel to redefine our purpose. In the face of uncertainty, we have the power to turn personal suffering into growth, resilience, and meaningful change.
I’m Still Here is a raw and unconventional exploration of identity, struggle, and reinvention. It reminds us that pain and adversity, rather than breaking us, can serve as catalysts for transformation.
Science thrives on collaboration, and I'm pleased to have built meaningful connections and gained new perspectives that will inspire my future work.
Attending the Winter Conference on Brain Research as a Travel Fellowship Awardee was an incredible opportunity to exchange ideas with peers across preclinical and clinical research. #WCBR #WCBR2025
Happy to be in beautiful Tahoe as a Travel Fellowship Awardee at the Winter Conference on Brain Research! If you're curious about interventional psychiatry, the opioid properties of #ketamine, and treatment-resistant #depression, stop by my poster tomorrow (Board #31)! #WinterBrain #WCBR2025
The NIH diversity supplement pages have all been pulled down. What is a diversity supplement and why should the public care? A diversity supplement is funding to help diversify the research workforce. You may be wondering, “so what?”. Let me explain. www.nigms.nih.gov/Pages/PageNo...
It was so nice meeting you too! Muito obrigado! :)